

Technical Review Panel Member

Curriculum Vitae

Name: Hind Satti

Nationality: Lesotho, USA

Additional languages: English, Arabic, Russian, Sesotho.

Expertise: TB, HIV, MDR TB, Health Systems Strengthening.

Qualifications

Qualification	Institution	Department	Year
Fellow Global Health	Harvard Medical School, Boston, USA	Department of global Health and Social Medicine	2008-todate
MPH, Harvard School of Public Health, Boston, MA 2012	Harvard School of public Health Boston, USA	Public Health	2010-2012
Postdoctoral Diploma, HIV Management (SA)	College of Medicine of South Africa	College of Medicine of South Africa	2005
Bachelor of Medicine and Surgery (MBBS)	Vitebsk Medical Institute, Belarus/CIS, 1994	Medical College	1994

Employment History

Employer	Position	Place	Year
Family Health International	Lead TB/HIV	USA /DC	2018-present
University Research Co., LLC	Senior HIV/TB/DR-TB Technical Advisor	USA/DC	2017-2018
Partners In Health	Deputy Clinical Director Global	Boston/USA	2015-2017
Partners In Health	Executive Country	Ethiopia/USA	2014-2017

	Director/Ethiopia		
Partner In Health	Executive Country Director		
Partners In Health	tor	Lesotho/Maseru	2009-2015

Relevant Publications

1. Sajjad SS, Sajid N, Fatimi A, Maqbool N, Baig-Ansari N, Amanullah F. The impact of structured counselling on patient knowledge at a private TB program in Karachi. *Pakistan Journal of Medical Sciences*. 2020;36(1):S49.
2. Wasserman I, Peters AW, Roa L, Amanullah F, Samad L. Breaking Specialty Silos: Improving Global Child Health Through Essential Surgical Care. *Global Health: Science and Practice*. 2020;8(2):183-
3. Malik AA, Brooks MB, Siddiqui S, Fuad J, Peloquin CA, Amanullah F, et al. Pharmacokinetics of levofloxacin in children treated for drug-resistant TB exposure. *Antimicrobial Agents and Chemotherapy*. 2019.
4. Amanullah F, Bacha JM, Fernandez LG, Mandalakas AM. Quality matters: Redefining child TB care with an emphasis on quality. *Journal of Clinical Tuberculosis and Other Mycobacterial Diseases*. 2019;17:100130.
5. Malik AA, Fuad J, Siddiqui S, Amanullah F, Jaswal M, Pmdcp ZB, et al. TB Preventive Therapy for individuals exposed to drug-resistant tuberculosis: feasibility and safety of a community-based delivery of fluoroquinolone-containing preventive regimen. *Clinical Infectious Diseases: an Official Publication of the Infectious Diseases Society of America*. 2019.
6. Malik AA, Brooks MB, Siddiqui S, Fuad J, Peloquin CA, Amanullah F, et al. Pharmacokinetics of levofloxacin in children treated for exposure to drug-resistant tuberculosis. *Antimicrobial agents and chemotherapy*. 2019;63(5).
7. Seddon JA, Whittaker E, Kampmann B, Lewinsohn DA, Osman M, Hesselning AC, et al. The evolving research agenda for paediatric tuberculosis infection. *The Lancet Infectious Diseases*. 2019;19(9):e322-e9.
8. Malik AA, Fuad J, Siddiqui S, Amanullah F, Jaswal M, Barry Z, et al. Tuberculosis Preventive Therapy for Individuals Exposed to Drug-resistant Tuberculosis: Feasibility and Safety of a Community-based Delivery of Fluoroquinolone-containing Preventive Regimen. *Clinical Infectious Diseases*. 2020;70(9):1958-65.
9. Malik AA, Becerra MC, Lash TL, Cranmer LM, Omer SB, Fuad J, et al. Risk factors for adverse events in household contacts prescribed preventive treatment for drug-resistant TB exposure. *Clinical Infectious Diseases*. 2020.
10. Seddon JA, Schaaf HS, Marais BJ, McKenna L, Garcia-Prats AJ, Hesselning AC, et al. Time to act on injectable-free regimens for children with multidrug-resistant tuberculosis. *The Lancet Respiratory Medicine*. 2018;6(9):662-4.
11. Detjen AK, McKenna L, Graham SM, Marais BJ, Amanullah F. The upcoming UN general assembly resolution on tuberculosis must also benefit children. *The Lancet Global Health*. 2018;6(5):e485-
12. Graham SM, Ahmed T, Amanullah F, Browning R, Cardenas V, Casenghi M, et al. Evaluation of tuberculosis diagnostics in children: 1. Proposed clinical case definitions for classification of intrathoracic tuberculosis disease. Consensus from an expert panel. *Journal of Infectious Diseases*. 2012;205(suppl_2):S199-S208.

13. Khan AJ, Khowaja S, Khan FS, Qazi F, Lotia I, Habib A, et al. Engaging the private sector to increase tuberculosis case detection: an impact evaluation study. *The Lancet infectious diseases*. 2012;12(8):608-16.
14. Seddon JA, Furin JJ, Gale M, Del Castillo Barrientos H, Hurtado RM, Amanullah F, et al. Caring for children with drug-resistant tuberculosis: practice-based recommendations. *American journal of respiratory and critical care medicine*. 2012;186(10):953-64.
15. Organization WH. Roadmap towards ending TB in children and adolescents. 2018.

16. IJTLD (March 2018) "Improving childhood Tuberculosis detection and treatment through facility-based screening in rural Pakistan' A. A. Malik, F. Amanullah, A. J. Codlin, S. Siddiqui, M. Jaswal, J. F. Ahmed, S. Saleem, A. Khurshid, H. Hussain.
17. Policy Brief (December 2015) Harvard Medical School Center for Global Health Delivery–Dubai "Post-Exposure Management of Multidrug-Resistant Tuberculosis Contacts: Evidence-Based Recommendations." James A. Seddon, Dorina Fred, Farhana Amanullah, H. Simon Schaaf, Jeffrey R. Starke, Salmaan Keshavjee, Joseph Burzynski, Jennifer J. Furin, Soumya Swaminathan, and Mercedes C. Becerra.
18. *Lancet* (December 2015) "Turning off the tap: stopping tuberculosis transmission through active case-finding and prompt effective treatment." Yuen CM, Amanullah F, Dharmadhikari A, Nardell EA, Seddon JA, Vasilyeva I, Zhao Y, Keshavjee S, Becerra MC.
19. PLOS ONE (October 2015) "Understanding Market Size and Reporting Gaps for Paediatric TB in Indonesia, Nigeria and Pakistan: Supporting Improved Treatment of Childhood TB in the Advent of New." Medicines Renia Coghlan¹, Elizabeth Gardiner, Farhana Amanullah, Chikwe Ihekweazu⁴, Rina Triasih, Malgorzata Grzemska, Charalambos Sismanidis.
20. IJTLD (November 2015) "Unmasking childhood tuberculosis in Pakistan- Efforts to improve child TB detection and management." Amanullah F, Malik A (Supplement - Improving access to better TB treatment for children)
21. *Lancet Infectious Diseases* (June 2015) "Towards earlier inclusion of children in tuberculosis drug trials: a consensus statement." Nachman S, Ahmed A, Amanullah F, Becerra MC, Botgros R, Brigden G, Browning R, Gardiner E, Hafner R, Hesselring A
22. *International Journal of Mycobacteriology* (April 2015) "IPT uptake among child contacts of TB patients: Experience from the Indus Hospital TB program, Karachi, Pakistan." Jafri R, Malik AA, Hussain H, Hussain S, Khatoon F, Asif K, Amanullah F.
23. *International Journal of Infectious Diseases* (March 2015) "Regional initiatives to address the challenges of tuberculosis in children perspectives from the Asia-Pacific region" Graham SM, Grzemska M, Brands A, Nguyen H, Amini J, Triasih R, Taludker K, Ahmed S, Amanullah F et. al.
24. IJTLD (April 2014) "High Tuberculosis prevalence in children exposed at home to drug resistant TB." Amanullah F, Ashfaq M, Khowaja S, Parekh A, Salahuddin N, Lotia-Farrukh I, Khan AJ, Becerra MC.
25. Public Health Action (March 2013) "Tuberculosis in children- getting started on the road to zero." Amanullah F, Graham SM.

26. Journal of Genetic Counseling (December 2013) Volume 22, 721-732 “The views of Pakistani doctors regarding genetic counseling services- Is there a future?” Ashfaq M, Amnaullah F, Ashfaq A, Ormond KE.
27. Journal of Infectious Diseases (2012 March) “Evaluation of Tuberculosis Diagnostics in Children: Proposed clinical case definitions for classification of intrathoracic tuberculosis disease. Consensus from an expert panel”. S.Graham, T.Ahmed, F. Amanullah, R. Browning et al.
28. Journal of Immunology 2004 Jul 1:173(1) 214-21 “Different co stimulatory and growth factor requirements for CD4+ and CD8+ T cell mediated rejection.” Vu MD, Amanullah F (first co-authors)
29. Journal of Immunology 2004 Feb 1:172(3) 1691-8 Critical role of OX40 in CD28 and CD154-independent rejection. Demirci G, Amanullah F et al.

Additional Information

World Health Organization

- Chair- Child and Adolescent TB Working Group- Stop TB Partnership, *October 2016-present*
- Member Stop TB Board- *March 2019-present*
- Member-Task Force on Global TB Research- *November 2018-present*
- Former member of the Strategic and Technical Advisory Group for TB (STAG), *2016-2019*
- Former member- Guideline Development Group (GDG), *May 2015- 2018*